Filing Details

Accession Number:
0001104659-17-015593
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-03-09 21:34:10
Reporting Period:
2017-03-07
Filing Date:
2017-03-09
Accepted Time:
2017-03-09 21:34:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1264587 Stemline Therapeutics Inc STML Pharmaceutical Preparations (2834) 450522567
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1456864 David Gionco C/O Stemline Therapeutics, Inc.
750 Lexington Avenue, Eleventh Floor
New York NY 10022
Chief Accounting Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-03-07 1,116 $8.13 95,914 No 4 S Direct
Common Stock Acquisiton 2017-03-09 70,299 $0.00 166,213 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 A Direct
Footnotes
  1. In connection with the vesting of 2,893 shares on March 6, 2017, a total of 1,116 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
  2. Reflects the weighted average sale price. The range of prices for such transaction is $8.08 to $8.15. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Of the 95,914 shares, 67,300 shares are restricted stock.
  4. The 70,299 restricted shares will vest in four installments as follows: 17,575 shares on March 9, 2018; 17,575 shares on March 9, 2019; 17,575 shares on March 9, 2020; and 17,574 shares on March 9, 2021.
  5. Of the 166,213 shares, 137,599 shares are restricted stock.